Screener
Gyre Therapeutics, Inc. GYRE Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Gyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Gyre Therapeutics, Inc.’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 5:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-340448
| Line item | Six Months Ended June 30, | Six Months Ended June 30, | Six Months Ended June 30, |
|---|---|---|---|
| Accrued expenses and other liabilities | 181 | 2,423 | |
| Operating lease liabilities | (536) | (559) | |
| Net proceeds from CVR liability settlement | — | 25 | |
| Net cash used in operating activities | (13,548) | (7,603) | |
| Investing Activities | |||
| Acquisition of intangible assets | (1,029) | (722) | |
| Purchase of certificates of deposit | (15,875) | (19,184) | |
| Purchase of available-for-sale securities | (2,032) | (11,224) |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Gyre Therapeutics, Inc.'s operating cash flow?
- Gyre Therapeutics, Inc. (GYRE) reported operating cash flow of -$16.73M in Q2 2026.
- How has Gyre Therapeutics, Inc.'s operating cash flow changed year-over-year?
- Gyre Therapeutics, Inc.'s operating cash flow decreased by 123.8% year-over-year, from -$7.47M to -$16.73M.
- What is the long-term trend for Gyre Therapeutics, Inc.'s operating cash flow?
- Over 2 years (2021 to 2023), Gyre Therapeutics, Inc.'s operating cash flow has grown at a -44.4% compound annual growth rate (CAGR), from -$83.76M to $25.89M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Gyre Therapeutics, Inc.'s operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude